Trial result ·
Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from the ROSEWOOD study.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This was a post hoc analysis of the mid-stage ROSEWOOD study. ROSEWOOD tested zanubrutinib plus obinutuzumab (ZO) against obinutuzumab alone (O). People had relapsed or refractory (R/R) follicular lymphoma (FL). They had received multiple earlier lines of therapy. In that study, PFS (progression-free survival) was longer with ZO. The median was 28.0 versus 10.4 months. The HR was 0.50 (CI 0.33 to 0.75). This analysis used the growth modulation index (GMI). It compares each person with their own last earlier treatment. A GMI of 1.33 or more was set as a sign of clinical activity.
What they found
Overall, median GMI was 2.7 in the ZO arm. The CI was 1.6 to 4.9. It was 0.9 in the O arm (CI 0.5 to 1.7). ZO gave longer PFS than the last earlier treatment did. This held in subgroups of interest in the ZO arm. Median GMI was 1.33 or more in all subgroups. Most people with R/R FL who got ZO had improved PFS. The comparison was with their last earlier treatment.
What it means for patients
The paper says this GMI analysis adds support for the benefit of ZO. It says ZO is a novel therapeutic option for people with R/R FL.
Why it is not certain yet
This was a post hoc analysis. It compared ZO with each person's own earlier treatment, not with another group.
Source
Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from the ROSEWOOD study.
PubMed · PMID 41922143We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Follicular lymphoma publications